Cardiac Assist Devices Market By Product (Left Ventricular Assist Devices, Right Ventricular Assist Devices, Biventricular Assist Devices, Percutaneous Ventricular Assist Devices, Total Artificial Hearts, Pediatric Ventricular Assist Devices, Controllers, Batteries, Power Units, and Accessories); By Application (Bridge to Transplantation, Destination Therapy, Bridge to Recovery, Bridge to Decision, Cardiogenic Shock, Acute Decompensated Heart Failure, Post-Cardiotomy Circulatory Failure, High-Risk Percutaneous Coronary Intervention, Biventricular Heart Failure, Pediatric Heart Failure); By End User (Cardiac and Heart Transplant Centers, Hospitals, Cardiac Surgery Centers, Catheterization Laboratories, Intensive Care Units, Pediatric Cardiac Centers, Ambulatory and Home-Care Support Providers); By Duration of Support (Temporary Cardiac Assist Devices, Short-Term Cardiac Assist Devices, Long-Term Durable Cardiac Assist Devices); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Cardiac Assist Devices Market: Patient-to-Implant Bottlenecks and Evidence-Sensitive Pump Demand Reshape Competition

The Global Cardiac Assist Devices Market is projected to grow from USD 2.5 billion in 2025 to USD 7.14 billion by 2032, expanding at a CAGR of 16.2%, according to Strategic Market Research.

 

The cardiac assist devices market is a procedure-led hospital market built around advanced heart failure and acute circulatory collapse. Demand begins when a specialist team determines that a patient requires mechanical circulatory support, meets clinical and reimbursement criteria, and can be treated at a hospital with the necessary surgical, interventional, and intensive-care capabilities.

 

The market includes left ventricular assist devices, right ventricular assist devices, biventricular support systems, temporary catheter-based pumps, total artificial hearts, paediatric support systems, controllers, batteries, power units, and replacement accessories. Extracorporeal membrane oxygenation remains commercially adjacent because it uses an external heart-lung circuit and follows a different equipment and consumables model.

 

Durable and temporary devices generate revenue through different pathways. Durable LVAD implantation creates an initial procedure and device sale followed by several years of accessories, monitoring, technical support, and replacement demand. Temporary pumps generate revenue for each acute episode and are more sensitive to cardiogenic-shock protocols, high-risk coronary intervention practices, clinical evidence, and hospital purchasing controls.

 

LVADs Dominate Long-Term Support, While RVADs and BiVADs Serve Smaller High-Complexity Segments

An LVAD supports the left ventricle, which pumps oxygenated blood into the body’s main circulation. An RVAD supports the right ventricle by moving oxygen-poor blood toward the lungs. BiVAD support assists both ventricles when neither side can maintain sufficient circulation.

LVADs form the central durable adult segment because most long-term implant activity involves severe left-ventricular failure. RVADs are used in a smaller population with isolated right-heart failure, post-cardiotomy deterioration, cardiogenic shock, or right-heart failure after LVAD implantation. BiVAD systems are reserved for severe biventricular failure and are concentrated in transplant centres and major cardiac-surgery programmes.

These categories are not commercially interchangeable. Durable LVADs can create years of recurring accessory revenue. RVAD and BiVAD support is more often associated with acute stabilisation, bridge-to-recovery treatment, surgical complications, or bridge-to-transplant care. Their value comes from high clinical intensity and limited alternatives rather than large procedure volumes.

 

The Addressable Population Is Far Smaller Than the Heart-Failure Burden

More than 64 million people live with heart failure worldwide, including nearly 6.7 million in the United States. These totals include patients ranging from early-stage outpatient cases to severe pump failure and should not be treated as direct device demand.

Approximately 5%–7% of symptomatic heart-failure patients may have advanced disease. Applying this range produces an analytical pool of roughly 3.2 million to 4.5 million people globally and approximately 335,000 to 469,000 in the United States. These figures represent patients who may require advanced evaluation, not confirmed LVAD candidates.

Many advanced-heart-failure patients have preserved or mildly reduced ejection fraction, severe right-sided disease, irreversible organ damage, active infection, frailty, inadequate caregiver support, or other conditions that make durable implantation unsuitable. Others recover with medical treatment, undergo transplantation, decline mechanical support, or never reach a specialist centre.

The supplied SMR working estimate places combined durable and temporary cardiac assist procedures at more than 38,000 annually worldwide and approximately 7,500 in the United States. The global figure should not be described as a count of permanent LVAD implants because it appears to include temporary support episodes. The U.S. estimate represents about 20% of the proposed procedure volume, while its estimated 39% share of global demand should be interpreted as revenue share rather than implant share. Higher procedure values, extensive temporary-pump use, recurring durable-device accessories, and specialist support allow U.S. revenue to exceed its share of unit volume.

 

Eligibility and Specialist-Centre Capacity Restrict Market Conversion

U.S. Medicare coverage shows how sharply the clinical funnel narrows. Durable LVAD candidates must have NYHA Class IV heart failure, a left ventricular ejection fraction of 25% or below, and additional evidence such as dependence on intravenous inotropes, low cardiac output despite medical therapy, or dependence on temporary mechanical support.

Coverage also depends on the treatment facility. Hospitals require a multidisciplinary VAD programme, experienced implanting surgeons, advanced-heart-failure cardiologists, critical-care teams, rehabilitation services, psychosocial assessment, patient education, and continuous emergency support.

A contemporary STS Intermacs study analysed 11,342 primary HeartMate 3 recipients treated at 176 U.S. centres. This limited specialist account base makes the market relationship-driven. Manufacturers must provide clinical training, emergency replacement, inventory support, programme development, and data reporting rather than rely on broad hospital distribution.

Late referral creates further leakage. Prolonged low cardiac output and venous congestion can impair kidney and liver function, worsen right-heart failure, and make a patient unsuitable for implantation. Stronger referral links between community cardiologists, regional hospitals, transplant programmes, and VAD centres can increase the number of patients assessed before irreversible deterioration.

 

Ejection Fraction Guides Durable LVAD Assessment but Does Not Define the Entire Market

Normal left ventricular ejection fraction is generally around 55%–70%. Heart failure with reduced ejection fraction is usually defined by an LVEF of 40% or below, while preserved ejection fraction generally refers to 50% or above.

Durable LVAD demand is concentrated in severe left-ventricular systolic failure, but an ejection fraction below 15%–20% is not a universal eligibility rule. Medicare uses a threshold of 25% or below alongside symptoms, haemodynamic status, treatment history, organ function, and multidisciplinary assessment.

Advanced heart failure is also not limited to reduced-ejection-fraction disease. Patients with preserved or mildly reduced ejection fraction can develop severe symptoms and repeated hospitalisations, but conventional durable left-sided pumps are not suitable for every phenotype. Broad Stage D estimates therefore overstate the directly addressable LVAD population.

Ischemic and nonischemic cardiomyopathy form the principal routes into durable support. Myocarditis and severe valve disease can also lead to acute or chronic mechanical-support requirements, but their shares vary across registries and should not be assigned fixed global percentages.

 

Durable LVAD Economics Shift Toward Installed-Base Revenue

STS Intermacs recorded 28,029 primary continuous-flow LVAD implants during 2015–2024. Patients receiving contemporary fully magnetically levitated devices achieved survival of 85.9% at one year, 60.2% at five years, and 51.8% at seven years. The same report stated that national durable-LVAD implant volumes remained stagnant despite improved outcomes.

Longer survival increases the commercial value of each implant. Supported patients require compatible controllers, batteries, mobile power products, replacement accessories, clinical monitoring, technical assistance, and emergency equipment throughout the support period.

The U.K. reported a median long-term VAD support duration of approximately 4.3 years. At the end of March 2025, 327 adults remained alive on long-term support, forming a recurring maintenance population even when annual implant volume declines.

European registry evidence also confirms repeat-procedure demand. EUROMACS recorded 6,962 implants in 6,408 patients across 32 centres in 17 countries, including 457 patients who underwent repeat implantation. Replacement procedures, accessories, field support, centre relationships, and patient longevity therefore contribute materially to durable-device revenue.

 

Transplant Capacity Sustains Bridge-to-Transplant Demand

The United States recorded 9,444 period-prevalent heart-transplant candidates in 2024, including 6,068 newly listed candidates, while 4,636 heart transplants were performed. These figures cannot be subtracted to calculate unmet LVAD demand because candidates enter and leave the waiting list for several reasons.

Not every transplant candidate requires an LVAD, and many destination-therapy recipients are not transplant candidates. The figures nevertheless demonstrate continued pressure within the transplant pathway. Durable LVADs can maintain patients while they wait for a donor heart, while destination therapy expands the market to selected patients who are unsuitable for transplantation.

 

Cardiogenic Shock Supports Temporary Pump Demand

Cardiogenic shock is the principal acute-care pathway for temporary mechanical support. Approximately 40,000–50,000 U.S. patients develop myocardial-infarction-associated cardiogenic shock each year, excluding shock caused by acute heart failure, myocarditis, surgery, valve complications, and other conditions.

The DAN-GER Shock trial strengthened the evidence for Impella CP in carefully selected patients with heart-attack-related cardiogenic shock. Mortality at 180 days was lower with the pump plus standard care than with standard care alone, although bleeding, limb ischaemia, haemolysis, renal-replacement therapy, and other complications increased.

The results support targeted use rather than unrestricted deployment. Hospitals need experienced shock teams, rapid patient identification, vascular-access expertise, intensive-care capacity, and the ability to manage complications.

NICE allowed percutaneous microaxial pumps to be used within the NHS for cardiogenic shock during an evidence-generation period beginning in March 2026. The pathway requires enhanced consent, outcome auditing, trained specialists, and centres with appropriate intensive-care expertise. Manufacturers must therefore support clinical data collection and training alongside product placement.

 

High-Risk PCI Has Entered a More Selective Phase

The CHIP-BCIS3 trial challenged routine planned microaxial pump use in haemodynamically stable patients undergoing complex high-risk PCI. The study found no overall clinical benefit and reported higher mortality measures in the pump group.

The commercial effect appeared in 2026, when Johnson & Johnson reported that U.S. Impella demand declined 2% in the second quarter after increasing 14% in the first quarter. The reversal was linked to evidence questioning pump use in certain high-risk coronary procedures.

This was an indication-specific decline rather than a broad fall in cardiac procedures. Temporary-pump protocols can change quickly because hospitals do not need to maintain a long-term implanted patient relationship. Future growth in high-risk PCI will depend on identifying narrower patient groups in which circulatory support produces a clear clinical benefit.

 

Safety Performance Influences Hospital Procurement

Product corrections create costs beyond replacing a defective device. Hospitals may need to revise procedures, retrain clinicians, inspect inventories, contact patients, replace accessories, and maintain additional backup equipment.

An FDA Class I correction involving Impella left-sided pumps covered 66,390 U.S. devices. The agency reported 129 serious injuries and 49 deaths associated with the risk of ventricular-wall perforation. The action involved updated instructions and warnings rather than complete market withdrawal.

Abbott also faced an FDA Class I action involving 882 HeartMate 3 implant kits because of possible blood leakage or air entering the connection between the inflow cannula and apical cuff. Reported events included 70 injuries and two deaths.

These actions increase the commercial importance of training, field support, surveillance, supply continuity, and reliable accessories. They also create greater concentration risk when hospitals have few alternative platforms.

 

North America Leads Revenue While Europe Remains Fragmented

North America remains the leading commercial region because it combines a large heart-failure population, established reimbursement, advanced transplant infrastructure, extensive temporary-pump use, and a sizeable durable-device installed base.

Europe has substantial clinical activity but operates through separate national reimbursement and procurement systems. EUROMACS recorded 6,962 implants across 17 countries, although registry participation does not represent complete European coverage.

Germany reported 809 VAD and total artificial heart procedures in 2024, including left-, right-, and biventricular devices. The U.K. completed 57 adult long-term bridge implants in 2024/25, down 24% from the previous year, alongside 94 short-term VAD procedures and 72 ECMO procedures. The reported 14% increase applies to short-term VAD and ECMO activity combined, not VADs alone.

 

Abbott and Abiomed Lead Different Commercial Segments

Abbott holds the strongest position in contemporary durable LVAD support through HeartMate 3. Its position strengthened after Medtronic stopped selling and distributing the HeartWare HVAD system in June 2021. HeartMate 3 subsequently became the only commercially available durable LVAD platform in the United States.

Abbott should be described as holding a near-single-platform position in the U.S. durable continuous-flow LVAD segment rather than a monopoly across every cardiac assist device category. Its advantage includes the installed patient base, compatible accessories, clinical evidence, and established relationships with implanting centres.

Johnson & Johnson MedTech leads temporary microaxial support through Abiomed’s Impella portfolio. J&J completed its approximately USD 16.6 billion acquisition of Abiomed in December 2022. Impella’s commercial strength comes from physician experience, hospital placement, clinical training, and use across cardiogenic-shock and selected coronary-intervention pathways.

Its revenue is more evidence-sensitive than durable LVAD revenue because hospitals can revise temporary-pump protocols quickly. The FDA’s December 2024 expansion of Impella CP and Impella 5.5 indications to specified paediatric patients created a strategically important but limited-volume opportunity at paediatric heart-failure and transplant centres.

 

Medtronic and Specialist Suppliers Serve Narrower Roles

Medtronic remains responsible for supporting patients previously implanted with the HVAD system but no longer competes for new durable LVAD procedures. Its role centres on legacy equipment, safety communications, patient support, and replacement components.

Getinge participates in adjacent extracorporeal support through Cardiohelp and Rotaflow systems. It should be included in the core market only when VA-ECMO and extracorporeal life-support equipment fall within the report scope.

SynCardia addresses severe biventricular failure through its FDA-approved temporary Total Artificial Heart, used as a bridge to transplantation. Unlike BiVAD support, which assists both native ventricles, a total artificial heart replaces their pumping function.

Berlin Heart serves the paediatric bridge-to-transplant segment through EXCOR Pediatric, which can provide left-sided or biventricular support in children who cannot use adult platforms.

CARMAT developed the Aeson total artificial heart for end-stage biventricular failure. Following insolvency proceedings, its activities transferred to CARMAT SAS in December 2025. Future competition depends on financing, manufacturing continuity, regulatory progress, and expansion beyond a small specialist-centre base.

 

Market Outlook: Lifecycle Value Replaces Broad Volume Assumptions

The cardiac assist devices market has a large upstream disease burden but a narrow commercial funnel. Market conversion depends on disease phenotype, the ventricle requiring support, haemodynamic deterioration, organ function, referral timing, patient acceptance, payer approval, and access to a qualified hospital programme.

Durable LVAD growth will be shaped by earlier referrals, destination therapy, repeat procedures, accessories, and revenue generated throughout the supported patient’s life. Improved survival makes field service and programme support more valuable even when first-time implant volumes remain stable.

RVAD and BiVAD demand will remain smaller and more closely linked to acute deterioration, surgical complications, biventricular failure, and transplant bridging. Temporary-pump demand will remain more volatile, with cardiogenic shock offering stronger evidence-based momentum and high-risk PCI moving toward more selective use.

Competitive strength will remain concentrated among suppliers that combine clinical evidence with training, emergency availability, reliable accessories, registry support, and post-market surveillance. Heart-failure prevalence creates the clinical need, but hospital capability and successful movement through the eligibility funnel determine market revenue.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.50 Billion
Revenue Forecast in 2032	USD 7.14 Billion
Overall Growth Rate	CAGR of 16.2% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Product, By Application, By End User, By Duration of Support, By Geography
By Product	Left Ventricular Assist Devices, Right Ventricular Assist Devices, Biventricular Assist Devices, Percutaneous Ventricular Assist Devices, Total Artificial Hearts, Pediatric Ventricular Assist Devices, Controllers, Batteries, Power Units, and Accessories
By Application	Bridge to Transplantation, Destination Therapy, Bridge to Recovery, Bridge to Decision, Cardiogenic Shock, Acute Decompensated Heart Failure, Post-Cardiotomy Circulatory Failure, High-Risk Percutaneous Coronary Intervention, Biventricular Heart Failure, Pediatric Heart Failure
By End User	Cardiac and Heart Transplant Centers, Hospitals, Cardiac Surgery Centers, Catheterization Laboratories, Intensive Care Units, Pediatric Cardiac Centers, Ambulatory and Home-Care Support Providers
By Duration of Support	Temporary Cardiac Assist Devices, Short-Term Cardiac Assist Devices, Long-Term Durable Cardiac Assist Devices
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, Mexico, Germany, UK, France, Italy, Spain, Netherlands, Switzerland, Sweden, China, Japan, India, South Korea, Australia, Singapore, Brazil, Argentina, Saudi Arabia, UAE, Israel, South Africa
Market Drivers	Rising advanced heart failure burden, growing shortage of donor hearts, wider use of durable LVADs in destination therapy, increasing adoption of temporary circulatory support in cardiogenic shock and high-risk PCI, technology advances in pumps, controllers, batteries, and pediatric assist systems
Customization Option	Available upon request